Long-term therapy with enalapril in patients with nephrotic-range proteinuria
- PMID: 8897561
- DOI: 10.1007/s004670050166
Long-term therapy with enalapril in patients with nephrotic-range proteinuria
Abstract
The effect of enalapril on urinary protein excretion and renal function was studied in six paediatric patients with various renal diseases causing nephroticrange proteinuria. In three younger children (aged 7-9 years) with steroid-resistant nephrotic syndrome, enalapril at a dose of 0.5 mg/kg per day given for 24 months yielded a temporary reduction of proteinuria in one child, a moderate and steady decrease in another and a complete disappearance of proteinuria in the third. Three adolescents, aged 17 years, took enalapril for 24 months at a dose of 20 mg/day. We observed no effect on proteiuria in one patient with Alport syndrome, a complete disappearance of urinary protein in one patient with membranoproliferative glomerulonephritis and a moderate decrease in the third patient who had idiopathic steroid-resistant nephrotic syndrome. Enalapril therapy resulted in an important reduction of proteinuria in two patients and a moderate decrease in three others. However this therapy was accompanied by a fall in glomerular filtration in all subjects, which was very marked in two patients. This fall in glomerular filtration may, however, simply reflect the natural course of the disease.
Similar articles
-
Enalapril: antiproteinuric effect in children with nephrotic syndrome.Clin Nephrol. 2000 Jun;53(6):432-6. Clin Nephrol. 2000. PMID: 10879662
-
Enalapril and prednisone in children with nephrotic-range proteinuria.Pediatr Nephrol. 2000 Oct;14(12):1088-91. doi: 10.1007/s004679900244. Pediatr Nephrol. 2000. PMID: 11045392
-
Efficacy of enalapril in the treatment of steroid resistant idiopathic nephrotic syndrome.J Assoc Physicians India. 1999 Feb;47(2):180-2. J Assoc Physicians India. 1999. PMID: 10999084 Clinical Trial.
-
Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.Acta Diabetol. 2005 Apr;42 Suppl 1:S42-9. doi: 10.1007/s00592-005-0180-4. Acta Diabetol. 2005. PMID: 15868119 Review.
-
Long-term renal effects of enalapril therapy in patients with renal insufficiency.Nephron. 1990;55 Suppl 1:49-58. doi: 10.1159/000186035. Nephron. 1990. PMID: 2189074 Review.
Cited by
-
Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome.Pediatr Nephrol. 2004 Jun;19(6):688-90. doi: 10.1007/s00467-004-1451-y. Epub 2004 Apr 3. Pediatr Nephrol. 2004. PMID: 15064939
-
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.BMC Nephrol. 2011 Feb 10;12:8. doi: 10.1186/1471-2369-12-8. BMC Nephrol. 2011. PMID: 21310077 Free PMC article. Clinical Trial.
-
Enalapril dosage in steroid-resistant nephrotic syndrome.Pediatr Nephrol. 2004 Jan;19(1):45-50. doi: 10.1007/s00467-003-1314-y. Epub 2003 Nov 25. Pediatr Nephrol. 2004. PMID: 14648339 Clinical Trial.
-
Outcomes of steroid-resistant nephrotic syndrome in children not treated with intensified immunosuppression.Pediatr Nephrol. 2023 May;38(5):1499-1511. doi: 10.1007/s00467-022-05762-4. Epub 2022 Oct 31. Pediatr Nephrol. 2023. PMID: 36315273 Free PMC article.
-
Enalapril in children with Alport syndrome.Pediatr Nephrol. 2004 Mar;19(3):271-5. doi: 10.1007/s00467-003-1366-z. Epub 2004 Jan 24. Pediatr Nephrol. 2004. PMID: 14745635 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources